In addition, another single-institution phase II study (NCT03256136) is evaluating Nivolumab plus chemotherapy, or Nivolumab in combination with Ipilimumab in EGFR or ALK mutated NSCLC patients who failed TKI therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.